<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00613574</url>
  </required_header>
  <id_info>
    <org_study_id>205.396</org_study_id>
    <nct_id>NCT00613574</nct_id>
  </id_info>
  <brief_title>RUSSE / Russian Spiriva® Safety &amp; Efficacy Study</brief_title>
  <official_title>RUSSE / Russian Spiriva® Safety &amp; Efficacy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      At the moment, there is hardly any structured safety and efficacy data collection on
      Tiotropium in Russia. Therefore, the objective of this observational study is to collect and
      evaluate data on bronchodilator efficacy and safety of Spiriva® (18 µg tiotropium inhalation
      capsules) delivered by HandiHaler®, in a national sample of Russian patients with varying
      severities of chronic obstructive pulmonary disease (COPD) in a real life setting over the 8
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this observational study is to collect and evaluate data on bronchodilator
      efficacy and safety of Spiriva® (18 µg tiotropium inhalation capsules) delivered by
      HandiHaler®, in national sample of Russian patients with varying severities of chronic
      obstructive pulmonary disease (COPD) in the real life setting over the 8 weeks.

      Study Hypothesis:

      Primary interest is given to observe change from baseline in post-dose FEV1 after 8 weeks.

      Comparison(s):

      The objective of this observational study is to collect and evaluate data on bronchodilator
      efficacy and safety of Spiriva® (18 mcg tiotropium inhalation capsules) delivered by
      HandiHaler®, in national sample of Russian patients with varying severities of chronic
      obstructive pulmonary disease (COPD) in a real life setting over the 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date>October 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Post-dose Forced Expiratory Volume in 1 Second After 8 Weeks</measure>
    <time_frame>baseline and final visit (8 weeks)</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) post-dose response at the end of the observation (Visit 3/week 8) versus (vs.) baseline (Visit 1/week 0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Forced Vital Capacity After 8 Weeks</measure>
    <time_frame>baseline and final visit (8 weeks)</time_frame>
    <description>Forced vital capacity (FVC) post-dose response at end of the observation (Visit 3/week 8 ) vs. baseline (Visit 1/week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Inspiratory Capacity (*Only Selected Sites) After 8 Weeks</measure>
    <time_frame>Visit 1 to Visit 3 (baseline and 8 weeks)</time_frame>
    <description>Inspiratory capacity (IC) post-dose response at end of the observation (Visit 3/week 8) vs. baseline (Visit 1/week 0) at selected sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Global Clinical Assessment of Efficacy at Final Visit by Severity, Full Analysis Set (FAS)</measure>
    <time_frame>final visit (8 weeks)</time_frame>
    <description>Patient Global Assessment of Spiriva® efficacy with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Global Clinical Assessment of Tolerability at Final Visit by Severity, FAS</measure>
    <time_frame>final visit (8 weeks)</time_frame>
    <description>Patient Global Assessment of Spiriva® tolerability with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physicians Global Clinical Assessment of Effect at Final Visit by Severity, FAS</measure>
    <time_frame>final visit (8 weeks)</time_frame>
    <description>Physician Global Assessment of Spiriva® efficacy with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physicians Global Clinical Assessment of Tolerability at Final Visit by Severity, FAS</measure>
    <time_frame>final visit (8 weeks)</time_frame>
    <description>Physician Global Assessment of Spiriva® tolerability with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
  </secondary_outcome>
  <enrollment type="Actual">407</enrollment>
  <condition>COPD</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium-bromide</intervention_name>
    <description>Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Physicians
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 40 years and older male and female ambulatory outpatients being seen in a
             participating physicians office for routine care

          2. Patients not previously treated with the Tiotropium

          3. Patients with clinical diagnosis of all stages of Chronic Obstructive Pulmonary
             Disease according to the current National Guidelines / 2004

          4. Current smokers or ex-smokers with a smoking history of &gt;=10 pack years

        Exclusion Criteria:

          1. Uncooperative patients as judged by the physician,

          2. Patients that have any condition which, according to the participating physicians
             opinion, might decrease the chance of obtaining satisfactory data to achieve the
             objectives of the observation,

          3. Patients with history of known preexisting or concomitant non-obstructive lung disease
             (e.g., sarcoidosis, tuberculosis, lung cancer),

          4. Patients currently enrolled in another clinical trial which requires a change in
             medication for their respiratory problems,

          5. Patients with any conditions listed in special precautions, drug interactions, and
             contraindication of Spiriva®'s Russian package insert, such as:

          6. Patients with known narrow-angle glaucoma,

          7. Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction,

          8. Patient with known moderate to severe renal impairment (creatinine clearance less than
             50 ml/min),

          9. Patients with a history of hypersensitivity to atropine or its derivatives, e.g.
             ipratropium or oxitropium or to any component of this product,

         10. Pregnant or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>BI Pharma Ges mbH Wien</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Khabarovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krasnodar region</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mezjdurechensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow Region</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>N. Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Ossetia</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>S-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stavropol region, North Ossetia</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stavropol</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vladivostok</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Voroneg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <results_first_submitted>October 29, 2009</results_first_submitted>
  <results_first_submitted_qc>December 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2010</results_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2014</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Spiriva® (Tiotropium Bromide)</title>
          <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Spiriva® (Tiotropium Bromide)</title>
          <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="407"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Post-dose Forced Expiratory Volume in 1 Second After 8 Weeks</title>
        <description>Forced expiratory volume in 1 second (FEV1) post-dose response at the end of the observation (Visit 3/week 8) versus (vs.) baseline (Visit 1/week 0)</description>
        <time_frame>baseline and final visit (8 weeks)</time_frame>
        <population>Full Analysis Set (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Spiriva® (Tiotropium Bromide)</title>
            <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-dose Forced Expiratory Volume in 1 Second After 8 Weeks</title>
          <description>Forced expiratory volume in 1 second (FEV1) post-dose response at the end of the observation (Visit 3/week 8) versus (vs.) baseline (Visit 1/week 0)</description>
          <population>Full Analysis Set (Intent-to-Treat population)</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Forced Vital Capacity After 8 Weeks</title>
        <description>Forced vital capacity (FVC) post-dose response at end of the observation (Visit 3/week 8 ) vs. baseline (Visit 1/week 0)</description>
        <time_frame>baseline and final visit (8 weeks)</time_frame>
        <population>Full Analysis Set (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Spiriva® (Tiotropium Bromide)</title>
            <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Forced Vital Capacity After 8 Weeks</title>
          <description>Forced vital capacity (FVC) post-dose response at end of the observation (Visit 3/week 8 ) vs. baseline (Visit 1/week 0)</description>
          <population>Full Analysis Set (Intent-to-Treat population)</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Inspiratory Capacity (*Only Selected Sites) After 8 Weeks</title>
        <description>Inspiratory capacity (IC) post-dose response at end of the observation (Visit 3/week 8) vs. baseline (Visit 1/week 0) at selected sites</description>
        <time_frame>Visit 1 to Visit 3 (baseline and 8 weeks)</time_frame>
        <population>Full Analysis Set (Intent-to-Treat population) and only patients from selected sites</population>
        <group_list>
          <group group_id="O1">
            <title>Spiriva® (Tiotropium Bromide)</title>
            <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Inspiratory Capacity (*Only Selected Sites) After 8 Weeks</title>
          <description>Inspiratory capacity (IC) post-dose response at end of the observation (Visit 3/week 8) vs. baseline (Visit 1/week 0) at selected sites</description>
          <population>Full Analysis Set (Intent-to-Treat population) and only patients from selected sites</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Global Clinical Assessment of Efficacy at Final Visit by Severity, Full Analysis Set (FAS)</title>
        <description>Patient Global Assessment of Spiriva® efficacy with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
        <time_frame>final visit (8 weeks)</time_frame>
        <population>Full Analysis Set (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Spiriva® (Tiotropium Bromide)</title>
            <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Global Clinical Assessment of Efficacy at Final Visit by Severity, Full Analysis Set (FAS)</title>
          <description>Patient Global Assessment of Spiriva® efficacy with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
          <population>Full Analysis Set (Intent-to-Treat population)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Global Clinical Assessment of Tolerability at Final Visit by Severity, FAS</title>
        <description>Patient Global Assessment of Spiriva® tolerability with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
        <time_frame>final visit (8 weeks)</time_frame>
        <population>Full Analysis Set (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Spiriva® (Tiotropium Bromide)</title>
            <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Global Clinical Assessment of Tolerability at Final Visit by Severity, FAS</title>
          <description>Patient Global Assessment of Spiriva® tolerability with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
          <population>Full Analysis Set (Intent-to-Treat population)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physicians Global Clinical Assessment of Effect at Final Visit by Severity, FAS</title>
        <description>Physician Global Assessment of Spiriva® efficacy with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
        <time_frame>final visit (8 weeks)</time_frame>
        <population>Full Analysis Set (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Spiriva® (Tiotropium Bromide)</title>
            <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Physicians Global Clinical Assessment of Effect at Final Visit by Severity, FAS</title>
          <description>Physician Global Assessment of Spiriva® efficacy with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
          <population>Full Analysis Set (Intent-to-Treat population)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physicians Global Clinical Assessment of Tolerability at Final Visit by Severity, FAS</title>
        <description>Physician Global Assessment of Spiriva® tolerability with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
        <time_frame>final visit (8 weeks)</time_frame>
        <population>Full Analysis Set (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Spiriva® (Tiotropium Bromide)</title>
            <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Physicians Global Clinical Assessment of Tolerability at Final Visit by Severity, FAS</title>
          <description>Physician Global Assessment of Spiriva® tolerability with a 4-point scale (1=excellent efficacy&amp;tolerability, 4=poor) at end of the observation (Visit 3/week 8).</description>
          <population>Full Analysis Set (Intent-to-Treat population)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Spiriva® (Tiotropium Bromide)</title>
          <description>Tiotropium bromide 18µg inhalation capsules once-daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Blastoma of Larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

